Acadia pharmaceuticals reports fourth quarter and full year 2021 financial results

San diego--(business wire)--acadia pharmaceuticals inc. (nasdaq: acad) today announced financial results for the fourth quarter and full year ended december 31, 2021. “acadia delivered strong fourth quarter and full year results with an increase in net sales of 10 percent year-over-year, driven by growth in both nuplazid prescriptions and market share,” said steve davis, chief executive officer. “we recently resubmitted our snda for pimavanserin for alzheimer's disease psychosis to the fda. in
ACAD Ratings Summary
ACAD Quant Ranking